search
Back to results

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy (EMLFO)

Primary Purpose

Short Bowel Syndrome, Necrotizing Enterocolitis, Small Intestine Perforation

Status
Completed
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
MicroLipid and fish oil
Routine care
Sponsored by
Wake Forest University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Short Bowel Syndrome focused on measuring Short bowel syndrome, Necrotizing enterocolitis, Small intestine perforation, Enterostomy, Intralipid, Microlipid, Fish oil

Eligibility Criteria

1 Day - 60 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • infants (age range: newborn to 2-month-old) who are admitted to BCH NICU with a jejunostomy or ileostomy (from surgical intervention for NEC, bowel perforation, midgut volvulus (twisted bowel), atresia or other gastrointestinal surgery);
  • who are expected to need full or partial PN for at least 21days from the day of enterostomy placement; and
  • have received enteral feedings ≤ 4 days since enterostomy placement

Exclusion Criteria:

  • infant with colostomy;
  • infants with enterostomy but

    • unable to obtain written informed consent from parent;
    • presence of congenital liver or renal, or metabolic diseases; and
    • ostomy caused by gastroschisis, omphalocele, imperforate anus, and perinatal asphyxia
    • unable to initiate enteral feeds after 28 days of ostomy placement.

Sites / Locations

  • WFUHS Brenner Children's Hospital NICU

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment

Control Group

Arm Description

The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.

Routine care

Outcomes

Primary Outcome Measures

Average duration of exposure to PN (including Intralipid, IL) between the initial feeding and bowel reanastomosis
We hypothesize that the average duration of exposure to PN/IL of the infants receiving ML/FO will be less than that of infants receiving usual care. The ratio of enteral to parenteral nutrition in the infants receiving ML/FO will be greater than that of infants receiving usual care.

Secondary Outcome Measures

Average weight gain (g/day)from initiating feeding to reanastomosis
We hypothesize that the average weight gain in infants receiving ML/FO will be greater than that of infants receiving usual care.
Average level of conjugated bilirubin and ostomy output of infants receiving ML/FO to the group receiving usual care between the initial feeding after placement of ostomy and reanastomosis
W hypothesize that the average level of conjugated bilirubin and ostomy output of infants receiving ML/FO will be less than that of infants receiving usual care.
Dietary fat and protein absorption, from initiating feeding to reanastomosis
Twenty-four hour stool (from ostomy) will be collected once per week after initiating feeding. Fecal fat and protein will be measured. Dietary fat and protein absorption will be calculated by subtracting fecal fat or protein from enteral dietary fat or protein, respectively. We hypothesize that infants receiving enteral ML/FO will have higher dietary fat and protein absorption than infants receiving routine care from initiating feeding to reanastomosis.
Expression of four key genes that play a crucial role in intestinal adaptation
RNA expression of four genes in small intestine, peptide YY (PYY), apical sodium dependent bile acid transport (ASBT), glucagon-like peptide-2 (GLP-2), and CD36 or fatty acid translocase (FAT), will be measured in both samples from stoma and distal mucous fistula sites.
Neurodevelopment outcomes and growth in the infants receiving ML/FO vs. in the infants receiving usual care at the 18-24 month of age.
We hypothesize that the early supplement of enteral ML/FO will have no adverse effect on the neurodevelopment outcomes and growth in the infants receiving ML/FO comparing to the infants receiving usual care at the 18-24 month of age.

Full Information

First Posted
March 1, 2011
Last Updated
August 13, 2018
Sponsor
Wake Forest University
search

1. Study Identification

Unique Protocol Identification Number
NCT01306838
Brief Title
Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy
Acronym
EMLFO
Official Title
Early Supplementation of Enteral Lipid With Combination of Microlipid and Fish Oil in Infants With Enterostomy
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
October 2014 (Actual)
Study Completion Date
October 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Necrotizing enterocolitis (NEC) and intestinal perforation are common in premature infants. Often surgery is needed to remove the dead bowel and create an ostomy (a temporary intestinal opening on the infant's abdomen). Infants with ostomies cannot digest and absorb food well, and must receive nutrition through the blood stream, i.e. parental nutrition (PN). However, prolonged dependence on PN can severely damage the liver and gut. Therefore, giving nutrition through the gut, i.e. enteral nutrition, is the primary treatment for infants with ostomies. Enteral fats, especially polyunsaturated fatty acids (PUFA), are most beneficial in stimulating gut mucosal adaptation, which begins 24 to 48 hours following bowel resection. In addition, the premature intestine has a rapid growth rate. It is likely that the current clinical practice of giving a relatively low-fat diet to infants with ostomies may not meet their high metabolic needs. The investigators hypothesize that increasing dietary fat content by early supplementation with MicroLipid® (ML, n-6 PUFA) and fish oil (FO, n-3 PUFA) to preserve the proper balance of n-6 and n-3 PUFA, may (i) improve bowel adaptation and infant growth; (ii) reduce the use of PN; and (iii) prevent liver damage and/or cholestasis (jaundice) in infants with ostomies.
Detailed Description
It is an interventional randomized open-labeled controlled trial with two groups: Treatment group: early supplementation of enteral lipid with ML and FO; Control group: routine care. The primary goal of this study is to obtain pilot data that will inform the subsequent design and execution of a large, randomized trial which will test the hypothesis that infants with short bowel syndrome or ostomy will experience beneficial growth effects from enteral nutrition supplemented with balanced n6/n-3 PUFA, a simple, inexpensive and noninvasive intervention. This pilot study will confirm the safety of PUFA supplemented enteral nutrition, establish the length and amount of enteral versus parenteral nutrition required, and determine the impact on infant growth and intestinal adaptation by measuring expression of four key genes that play a crucial role in intestinal adaptation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Short Bowel Syndrome, Necrotizing Enterocolitis, Small Intestine Perforation
Keywords
Short bowel syndrome, Necrotizing enterocolitis, Small intestine perforation, Enterostomy, Intralipid, Microlipid, Fish oil

7. Study Design

Primary Purpose
Other
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
The treatment arm is given early enteral supplementation with MicroLipid and Fish oil.
Arm Title
Control Group
Arm Type
Active Comparator
Arm Description
Routine care
Intervention Type
Dietary Supplement
Intervention Name(s)
MicroLipid and fish oil
Intervention Description
Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
Intervention Type
Other
Intervention Name(s)
Routine care
Intervention Description
Routine care
Primary Outcome Measure Information:
Title
Average duration of exposure to PN (including Intralipid, IL) between the initial feeding and bowel reanastomosis
Description
We hypothesize that the average duration of exposure to PN/IL of the infants receiving ML/FO will be less than that of infants receiving usual care. The ratio of enteral to parenteral nutrition in the infants receiving ML/FO will be greater than that of infants receiving usual care.
Time Frame
up to three years
Secondary Outcome Measure Information:
Title
Average weight gain (g/day)from initiating feeding to reanastomosis
Description
We hypothesize that the average weight gain in infants receiving ML/FO will be greater than that of infants receiving usual care.
Time Frame
up to three years
Title
Average level of conjugated bilirubin and ostomy output of infants receiving ML/FO to the group receiving usual care between the initial feeding after placement of ostomy and reanastomosis
Description
W hypothesize that the average level of conjugated bilirubin and ostomy output of infants receiving ML/FO will be less than that of infants receiving usual care.
Time Frame
up to three years
Title
Dietary fat and protein absorption, from initiating feeding to reanastomosis
Description
Twenty-four hour stool (from ostomy) will be collected once per week after initiating feeding. Fecal fat and protein will be measured. Dietary fat and protein absorption will be calculated by subtracting fecal fat or protein from enteral dietary fat or protein, respectively. We hypothesize that infants receiving enteral ML/FO will have higher dietary fat and protein absorption than infants receiving routine care from initiating feeding to reanastomosis.
Time Frame
up to three years
Title
Expression of four key genes that play a crucial role in intestinal adaptation
Description
RNA expression of four genes in small intestine, peptide YY (PYY), apical sodium dependent bile acid transport (ASBT), glucagon-like peptide-2 (GLP-2), and CD36 or fatty acid translocase (FAT), will be measured in both samples from stoma and distal mucous fistula sites.
Time Frame
up to four years
Title
Neurodevelopment outcomes and growth in the infants receiving ML/FO vs. in the infants receiving usual care at the 18-24 month of age.
Description
We hypothesize that the early supplement of enteral ML/FO will have no adverse effect on the neurodevelopment outcomes and growth in the infants receiving ML/FO comparing to the infants receiving usual care at the 18-24 month of age.
Time Frame
up to 4.5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
60 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: infants (age range: newborn to 2-month-old) who are admitted to BCH NICU with a jejunostomy or ileostomy (from surgical intervention for NEC, bowel perforation, midgut volvulus (twisted bowel), atresia or other gastrointestinal surgery); who are expected to need full or partial PN for at least 21days from the day of enterostomy placement; and have received enteral feedings ≤ 4 days since enterostomy placement Exclusion Criteria: infant with colostomy; infants with enterostomy but unable to obtain written informed consent from parent; presence of congenital liver or renal, or metabolic diseases; and ostomy caused by gastroschisis, omphalocele, imperforate anus, and perinatal asphyxia unable to initiate enteral feeds after 28 days of ostomy placement.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Qing Yang, MD, PhD
Organizational Affiliation
Wake Forest Univeristy Health Science
Official's Role
Principal Investigator
Facility Information:
Facility Name
WFUHS Brenner Children's Hospital NICU
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
20531250
Citation
Yang Q, Kock ND. Effects of dietary fish oil on intestinal adaptation in 20-day-old weanling rats after massive ileocecal resection. Pediatr Res. 2010 Sep;68(3):183-7. doi: 10.1203/PDR.0b013e3181eb2ee5.
Results Reference
background
PubMed Identifier
22447320
Citation
Yang Q, Lan T, Chen Y, Dawson PA. Dietary fish oil increases fat absorption and fecal bile acid content without altering bile acid synthesis in 20-d-old weanling rats following massive ileocecal resection. Pediatr Res. 2012 Jul;72(1):38-42. doi: 10.1038/pr.2012.41. Epub 2012 Mar 23.
Results Reference
background
PubMed Identifier
20980771
Citation
Yang Q, Welch CD, Ayers K, Turner C, Pranikoff T. Early enteral fat supplementation with microlipid(R) and fish oil in the treatment of two premature infants with short bowel. Neonatology. 2010;98(4):348-53. doi: 10.1159/000316067. Epub 2010 Oct 27.
Results Reference
result
Citation
Woods CW, Ayers K, Turner C, Pranikoff T and Yang Q. A Novel Nutritional Approach to Prevent Parenteral Nutrition-Associated Cholestasis in Two Premature Infants with Short Bowel Syndrome. ICAN: Infant, Child, & Adolescent Nutrition 2013 5: 32-36
Results Reference
result
PubMed Identifier
23453547
Citation
Yang Q, Ayers K, Chen Y, Helderman J, Welch CD, O'Shea TM. Early enteral fat supplement and fish oil increases fat absorption in the premature infant with an enterostomy. J Pediatr. 2013 Aug;163(2):429-34. doi: 10.1016/j.jpeds.2013.01.056. Epub 2013 Feb 28.
Results Reference
result
PubMed Identifier
27856001
Citation
Younge N, Yang Q, Seed PC. Enteral High Fat-Polyunsaturated Fatty Acid Blend Alters the Pathogen Composition of the Intestinal Microbiome in Premature Infants with an Enterostomy. J Pediatr. 2017 Feb;181:93-101.e6. doi: 10.1016/j.jpeds.2016.10.053. Epub 2016 Nov 15.
Results Reference
derived
PubMed Identifier
24603562
Citation
Yang Q, Ayers K, Chen Y, O'Shea TM. Early enteral fat supplementation improves protein absorption in premature infants with an enterostomy. Neonatology. 2014;106(1):10-6. doi: 10.1159/000357554. Epub 2014 Mar 6.
Results Reference
derived

Learn more about this trial

Early Provision of Enteral Microlipid and Fish Oil to Infants With Enterostomy

We'll reach out to this number within 24 hrs